These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22011479)

  • 1. Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population.
    Koga T; Okada A; Kawashiri S; Kita J; Suzuki T; Nakashima Y; Tamai M; Satoh K; Origuchi T; Iwamoto N; Yamasaki S; Nakamura H; Migita K; Ida H; Ueki Y; Eguchi K; Kawakami A
    Clin Exp Rheumatol; 2011; 29(5):811-5. PubMed ID: 22011479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
    Ulijn E; den Broeder N; Wientjes M; van Herwaarden N; Meek I; Tweehuysen L; van der Maas A; van den Bemt BJ; den Broeder AA
    Ann Rheum Dis; 2020 Jul; 79(7):867-873. PubMed ID: 32317314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MIF and TNFα serum levels in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: a cross-sectional study.
    Brennan-Bourdon LM; De la Cruz-Mosso U; Reyes-Castillo Z; Martínez-Bonilla GE; Ramírez-Dueñas MG; Islas-Carbajal MC; Rincón-Sánchez AR; Salazar-Páramo M; Muñoz-Valle JF
    Immunopharmacol Immunotoxicol; 2015 Apr; 37(2):207-13. PubMed ID: 25721154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.
    Choi IY; Gerlag DM; Herenius MJ; Thurlings RM; Wijbrandts CA; Foell D; Vogl T; Roth J; Tak PP; Holzinger D
    Ann Rheum Dis; 2015 Mar; 74(3):499-505. PubMed ID: 24297376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers.
    Lequerré T; Farran É; Ménard JF; Kozyreff-Meurice M; Vandhuick T; Tharasse C; Pouplin S; Daragon A; Le Loët X; Varin R; Vittecoq O
    Joint Bone Spine; 2015 Oct; 82(5):330-7. PubMed ID: 25864942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TROVE2 Antibody Determined by Immune-Related Array May Serve as a Predictive Marker for Adalimumab Immunogenicity and Effectiveness in RA.
    Chen PK; Lan JL; Chen YM; Chen HH; Chang SH; Chung CM; Rutt NH; Tan TM; Mamat RNR; Anuar ND; Blackburn JM; Chen DY
    J Immunol Res; 2021; 2021():6656121. PubMed ID: 33763493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis.
    Cuchacovich M; Catalan D; Wainstein E; Gatica H; Soto L; Aravena O; Pesce B; Sabugo F; Aguillón JC
    Clin Exp Rheumatol; 2008; 26(6):1067-73. PubMed ID: 19210871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis.
    Wijbrandts CA; van Leuven SI; Boom HD; Gerlag DM; Stroes EG; Kastelein JJ; Tak PP
    Ann Rheum Dis; 2009 Aug; 68(8):1316-21. PubMed ID: 18723565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice.
    Kaneko A; Hirano Y; Fujibayashi T; Hattori Y; Terabe K; Kojima T; Ishiguro N
    Mod Rheumatol; 2013 May; 23(3):466-77. PubMed ID: 22895833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis.
    Guo X; Wang S; Godwood A; Close D; Ryan PC; Roskos LK; White WI
    Int J Rheum Dis; 2019 Apr; 22(4):646-653. PubMed ID: 30358109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis.
    Chen DY; Chen YM; Tsai WC; Tseng JC; Chen YH; Hsieh CW; Hung WT; Lan JL
    Ann Rheum Dis; 2015 Mar; 74(3):e16. PubMed ID: 24442879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
    Keystone EC; Haraoui B; Guérette B; Mozaffarian N; Liu S; Kavanaugh A
    J Rheumatol; 2014 Feb; 41(2):235-43. PubMed ID: 24293583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Percentage of Signal Regulatory Protein α/β
    Magill L; Adriani M; Berthou V; Chen K; Gleizes A; Hacein-Bey-Abina S; Hincelin-Mery A; Mariette X; Pallardy M; Spindeldreher S; Szely N; Isenberg DA; Manson JJ; Jury EC; Mauri C
    Front Immunol; 2018; 9():2865. PubMed ID: 30568660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study.
    Hoxha A; Calligaro A; Tonello M; Ramonda R; Carletto A; Paolazzi G; Bortolotti R; Del Ross T; Grava C; Boaretto M; Favaro M; Teghil V; Ruffatti A; Punzi L
    Joint Bone Spine; 2016 Mar; 83(2):167-71. PubMed ID: 26750762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients.
    Ito S; Kobayashi D; Hasegawa E; Takai C; Nemoto T; Lee H; Abe A; Otani H; Ishikawa H; Murasawa A; Narita I; Nakazono K
    Intern Med; 2019 Feb; 58(4):511-519. PubMed ID: 30210123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.
    Fleischmann R; Goldman JA; Leirisalo-Repo M; Zanetakis E; El-Kadi H; Kellner H; Bolce R; DeHoratius R; Wang J; Decktor D
    Curr Med Res Opin; 2014 Nov; 30(11):2139-49. PubMed ID: 25050591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course.
    Llamas-Covarrubias MA; Valle Y; Navarro-Hernández RE; Guzmán-Guzmán IP; Ramírez-Dueñas MG; Rangel-Villalobos H; Estrada-Chávez C; Muñoz-Valle JF
    Rheumatol Int; 2012 Aug; 32(8):2307-11. PubMed ID: 21607559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab decreases aortic stiffness independently of its effect in disease activity in patients with rheumatoid arthritis.
    Vassilopoulos D; Gravos A; Vlachopoulos C; Kandili A; Ioakeimidis N; Pectasides D; Stefanadis C
    Clin Rheumatol; 2015 Feb; 34(2):359-64. PubMed ID: 24928345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis.
    Badot V; Galant C; Nzeusseu Toukap A; Theate I; Maudoux AL; Van den Eynde BJ; Durez P; Houssiau FA; Lauwerys BR
    Arthritis Res Ther; 2009; 11(2):R57. PubMed ID: 19389237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.